Certest Presents Newly-Released SARS-CoV-2 Diagnostic Products at AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 29 Sep 2021

Image: VIASURE Real Time PCR Detection Kit (Photo courtesy of CerTest Biotec)

CerTest Biotec (Zaragoza, Spain) introduced all the new releases developed by the company in recent months, especially its products focused on the diagnosis of SARS-CoV-2, at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

Dedicated to achieving better health through laboratory medicine, the American Association for Clinical Chemistry, AACC, brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking laboratory science.

Among its new releases highlighted by CerTest at AACC 2021 were the VIASURE Tropical Panel I Real Time PCR Detection Kit designed for the specific and differentiation of Zika (ZIKV), Dengue (DENV), Chikungunya (CHIKV), West Nile (WNV), Yellow fever (YFV) and/or Mayaro (MYV) viruses; and the FOB Turbilatex non-invasive immunological test for bowel cancer screening.

CerTest’s new products for the diagnosis of SARS-CoV-2 that were exhibited at the event included the CerTest CLIA SARS-CoV-2 Plate which is an antigen detection product; the CerTest SARS-CoV-2 one step card test which is a colored chromatographic immunoassay for the qualitative detection of SARS-CoV-2 from nasopharyngeal swab samples from patients with sign and symptoms of COVID-19 infection; and the VIASURE SARS-CoV-2 Variant II Real Time PCR Detection Kit for the qualitative detection of RNA from genetic mutations in the S gene (P681R, L452R and E484Q) from positive SARS-CoV-2 nasopharyngeal samples.

CerTest also used the event as a launching pad for its new Business Units: CerTest CLIA, BioSynProbes and CerTest Vaccines, which were represented at the company’s booth. According to the company, the new business units will complete the portfolio of comprehensive solutions not only for the diagnosis of infectious diseases, but also in the manufacturing processes of clinical tests and disease cure.

Related Links:
CerTest Biotec

Visit expo >

Platinum Member

Automated Coagulation Analyzer

Hemolumi H6

βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®

All-in-One Molecular System

AIO M160

Gold Member

Automatic Hematology Analyzer

CF9600

Latest AACC 2021 News

Channels

Clinical Chemistry

view channel

Blood-Based Score May Support Targeted Interventions for Healthier Aging

Chronic diseases frequently accumulate with age, complicating efforts to maintain functional independence in older adults. Studies cited by the investigators indicate that about 60% of people over age... Read more

Image: Two major international studies identified noninvasive tests that can accurately diagnose and assess MASLD and MASH, reducing reliance on liver biopsy. (Image Credit: Adobe Stock)

Noninvasive Tests Offer Alternatives to Biopsy for Assessing Advanced Liver Scarring

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to one in three adults worldwide and as many as seven in 10 people with obesity or type 2 diabetes. Its more severe form, metabolic... Read more

Image: A new study identified 17 plasma proteins linked to mortality in older adults, several of which also track biological ageing across multiple organ systems. (Image Credit: Adobe Stock)

Blood Proteins Linked to Mortality Risk and Biological Aging Across Organ Systems

Older adults of the same chronological age can differ markedly in health, chronic disease burden, and resilience. Biological age aims to capture these differences by reflecting how rapidly the body and... Read more

$Image: Distinct tau isoform signatures in Alzheimer\'s disease and amyotrophic lateral sclerosis. (Abu-Rumeileh, S., Großkopf, H., Guthknecht, A. et al. Nature Communications, 2026. DOI: 10.1038/s41467-026-78390-3)$

Two-Step Blood Test Improves Specificity for Alzheimer’s Diagnosis

Early Alzheimer’s disease can be difficult to identify before more severe cognitive symptoms emerge. Blood tests measuring phosphorylated tau protein p-tau217 may help detect disease-related changes, but... Read more

Molecular Diagnostics

view channel

$Image: These images show breast tumors in a new preclinical model developed by Garvan researchers. The cells carry a fluorescent sensor that lights up blue/green when CDK1—the protein \'engine\' cells need to divide—is switched on. Using it, the team watched CDK1 activity rise as tumors became invasive and stay high in tumors that kept growing despite treatment. (Image Credit: Dr. Max Nobis / Garvan Institute)$